Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
about
Impact of virologic breakthrough and HBIG regimen on hepatitis B recurrence after liver transplantationOutcomes of patients with hepatitis B who developed antiviral resistance while on the liver transplant waiting listUltradeep Sequencing for Detection of Quasispecies Variants in the Major Hydrophilic Region of Hepatitis B Virus in Indonesian Patients.Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patients.Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B.Molecular testing in the diagnosis and management of chronic hepatitis BVirologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach.Use of massively parallel ultradeep pyrosequencing to characterize the genetic diversity of hepatitis B virus in drug-resistant and drug-naive patients and to detect minor variants in reverse transcriptase and hepatitis B S antigen.Comparison of next-generation sequencing and clone-based sequencing in analysis of hepatitis B virus reverse transcriptase quasispecies heterogeneity.Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes.Sensitive assay for quantification of hepatitis B virus mutants by use of a minor groove binder probe and peptide nucleic acids.Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.Sustained virological and biochemical responses to lamivudine and adefovir dipivoxil combination in a chronic hepatitis B infection despite mutations conferring resistance to both drugs.Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.New developments in HBV molecular diagnostics and quantitative serology.Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology.Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice.Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?Evaluation of peptide nucleic acid array for the detection of hepatitis B virus mutations associated with antiviral resistance.Failure of adefovir 20 mg to improve suboptimal response in lamivudine-resistant hepatitis B patients treated with adefovir 10 mg and lamivudine.Quasispecies variant of pre-S/S gene in HBV-related hepatocellular carcinoma with HBs antigen positive and occult infection.Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy.
P2860
Q30431207-9CA7C6A5-F40C-4A9B-82D2-D4DD7D8E1E92Q30440211-3639A3FF-B7E6-42B2-A205-5704FBF3F7F6Q35706679-B296BDED-5168-4FD7-8EAF-2B599794B0D6Q35964704-38FADD87-CEEE-4426-82DC-2D4388E21FE5Q36757579-75A2CB99-50A7-4DB2-9B1D-827C7A271158Q36881140-54A6365B-5E42-42F2-9C1E-79384E4ECFADQ37074608-9B8C4C53-F526-417D-9114-F130BDC3A426Q37099761-DC34F321-E0C2-4FBA-A438-CD0A1D4FCA08Q37336272-1CAF91BA-D7B0-4422-97CF-775811282EEBQ40077714-FBA99E74-6302-4732-97F0-1AB3273B318FQ41428508-2EA3DFB3-9102-4FF1-833A-AA0342C4DF0CQ42000973-7B08CD27-5F7A-41EA-BAE5-A289388AC5C8Q42007992-CA864F18-1423-42A7-83B5-606D90F11750Q42124703-4BA17059-855A-4D4C-966D-39628BBF67A8Q42590818-DACC287D-4241-41AA-A950-C75585CC7F32Q42910007-84E80C73-AC26-4201-8D3A-891FDD8E4C61Q43071697-FD189638-8E05-4BB1-AD7D-B7BEFC5AA7D4Q43445015-8969049F-D74C-4E9C-93A5-F6301BCA4BBBQ44087733-362D552E-74A0-4D7B-8E53-D3DC610F5861Q45366377-4121353C-F3E9-4EFA-B951-53A30DCD78B6Q46195637-90A06EE6-D287-464E-8C50-110DB3F84B48Q49612948-A720DBB9-8721-45B2-99FA-3A281F70FB52Q53478108-621DE0FA-0595-4C36-BFD6-2049D0C048B6
P2860
Sensitive line probe assay that simultaneously detects mutations conveying resistance to lamivudine and adefovir.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@ast
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@en
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@nl
type
label
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@ast
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@en
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@nl
prefLabel
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@ast
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@en
Sensitive line probe assay tha ...... ce to lamivudine and adefovir.
@nl
P2093
P2860
P1476
Sensitive line probe assay tha ...... nce to lamivudine and adefovir
@en
P2093
Anna S F Lok
Erwin Sablon
Evelien Libbrecht
Munira Hussain
Scott Fung
P2860
P304
P356
10.1128/JCM.44.3.1094-1097.2006
P407
P577
2006-03-01T00:00:00Z